Oncology (all articles)
RCT: Axicabtagene Ciloleucel as second-line therapy for Large B-Cell Lymphoma.
30 Jan, 2022 | 13:41h | UTC
Commentary on Twitter
In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy. #ASH21 https://t.co/V1WfVJ2k9V pic.twitter.com/ZHUhx8es27
— NEJM (@NEJM) December 11, 2021
Perspective | Ultrahypofractionated radiotherapy for localized prostate cancer: how far can we go?
28 Jan, 2022 | 08:09h | UTC
M-A: Clinical and endoscopic characteristics associated with post-endoscopy upper gastrointestinal cancers.
28 Jan, 2022 | 08:08h | UTCClinical and Endoscopic Characteristics Associated with Post-Endoscopy Upper Gastrointestinal Cancers: a Systematic Review and Meta-analysis – Gastroenterology (link to abstract – $ for full-text)
Long-Term Results of RCT: Neoadjuvant chemoradiotherapy vs. upfront surgery for resectable and borderline resectable pancreatic cancer.
28 Jan, 2022 | 08:01h | UTCNeoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Impact of the COVID‐19 pandemic on pediatric oncology providers globally: A mixed‐methods study.
27 Jan, 2022 | 09:46h | UTCNews Release: How has the COVID-19 pandemic impacted clinicians who care for children with cancer? – Wiley
Review | Immune-checkpoint inhibitors: long-term implications of toxicity.
27 Jan, 2022 | 09:39h | UTCImmune-checkpoint inhibitors: long-term implications of toxicity – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (@CardioOncology) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity' https://t.co/7ymExYiqEY #ImmunoOnc #medonc pic.twitter.com/m6m92mZwOZ
— NatureRevClinOncol (@NatRevClinOncol) January 26, 2022
M-A: Late kidney effects of nephron-sparing vs. radical nephrectomy for Wilms Tumor.
27 Jan, 2022 | 09:22h | UTCLate Kidney Effects of Nephron-Sparing vs Radical Nephrectomy for Wilms Tumor: A Systematic Review and Meta-Analysis – The Journal of Urology (link to abstract – $ for full-text)
Systematic Review: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent.
27 Jan, 2022 | 09:15h | UTC
Fever of unknown origin and incidence of cancer: a population-based cohort study using nationwide Danish registries showed that cancer risk in one year was 1.2%.
26 Jan, 2022 | 01:36h | UTCFever of unknown origin and incidence of cancer – Clinical Infectious Diseases (link to abstract – $ for full-text)
Review: Genotypic and phenotypic characteristics of hereditary colorectal cancer.
26 Jan, 2022 | 01:16h | UTCGenotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer – Annals of Coloproctology
ASCO-SNO Guideline: Therapy for diffuse astrocytic and oligodendroglial tumors in adults.
26 Jan, 2022 | 01:19h | UTC
Review: Treatment for peritoneal metastasis of patients with colorectal cancer.
26 Jan, 2022 | 01:17h | UTCTreatment for Peritoneal Metastasis of Patients With Colorectal Cancer – Annals of Coloproctology
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
25 Jan, 2022 | 09:28h | UTC
M-A: BRCA1 and BRCA2 pathogenic variants and prostate cancer risk.
25 Jan, 2022 | 09:01h | UTC
Review: Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
25 Jan, 2022 | 08:59h | UTC
Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.
24 Jan, 2022 | 08:08h | UTCOutcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Related:
Commentary on Twitter:
In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding
8-year DMFI 97%
8-year BCSS 99.6%Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE
— Paolo Tarantino (@PTarantinoMD) January 22, 2022
RCT: The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing esophageal cancer did not improve outcomes.
24 Jan, 2022 | 08:04h | UTCTrastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase III trial in 203 pts with HER2+ oesophageal cancer, adding trastuzumab to neoadjuvant CRT did not significantly improve mDFS (19.6 vs 14.2 months; HR 0.99; P = 0.97). The incidence of grade 3 and 4 TRAEs was 43% & 21% vs 54% & 22%: https://t.co/wx0NmVMyCR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) January 21, 2022
Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials.
24 Jan, 2022 | 07:49h | UTC
Commentary from the author on Twitter (thread – click for more)
Our new paper is out now in @JAMANetworkOpen !
When a randomized trial designs a « Physicians’ choice » or « Investigators’ choice » control arm, you might think :
« Great, the control arm is standard of care ! »
➡️ you may be surprised 🧵👇🏻https://t.co/uho2pvXcG5— Timothée Olivier, MD (@Timothee_MD) January 21, 2022
RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.
21 Jan, 2022 | 09:46h | UTCLenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Commentary on Twitter
In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively. https://t.co/lzqFDnhAQn pic.twitter.com/Tm2BJZuh1D
— NEJM (@NEJM) January 19, 2022
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
21 Jan, 2022 | 09:36h | UTCTreatment for Brain Metastases: ASCO-SNO-ASTRO Guideline – Journal of Clinical Oncology
15th Report on Carcinogens now includes 256 listings of substances that are known or reasonably anticipated to cause cancer in humans.
21 Jan, 2022 | 09:34h | UTC15th Report on Carcinogens – National Toxicology Program
Commentary on Twitter
8 substances have been added to the 15th report on Carcinogens, bringing the total list to 256 substances that are known, or reasonably anticipated, to cause cancer in humanshttps://t.co/r1e9Bv8hIU pic.twitter.com/BVGt809g2T
— K Pavithran (@drkpavithran) December 23, 2021
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
21 Jan, 2022 | 09:31h | UTCThe validity of progression-free survival 2 as a surrogate trial end point for overall survival – Cancer (link to abstract – $ for full-text)
RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.
21 Jan, 2022 | 09:28h | UTCPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
20 Jan, 2022 | 08:57h | UTC
Commentary on Twitter
Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC
Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB
— Paolo Tarantino (@PTarantinoMD) January 18, 2022
O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.
20 Jan, 2022 | 08:59h | UTC